Research Article

Anti-MUC1 Antibody in Nipple Aspirate Fluids Correlates with Tumor Aggressiveness in Breast Cancer: A Feasibility Study

Ebru Menekse,¹ John McKolanis,² Olivera J. Finn,² Priscilla F. McAuliffe,¹ Ronald Johnson,¹ and Atilla Soran¹

¹Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, Pittsburgh, PA 15213, USA
²Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA

Correspondence should be addressed to Atilla Soran; asoran@upmc.edu

Received 19 June 2015; Revised 27 October 2015; Accepted 11 November 2015

1. Introduction

Breast cancer (BC) is the most common cancer and it is also the second most frequent cause of cancer deaths among women in the USA, accounting for an estimated 231,840 new cases and 40,290 deaths for women in the USA in 2015 [1, 2]. Improvements in BC survival have come with early diagnosis of high risk women using mammograms and improved chemo- and hormonotherapy regimens for the last 3 decades [3]. However, there is a critical need to develop technically feasible, less invasive, inexpensive, and reliable methods to allow earlier diagnosis, identify aggressive phenotypes, and monitor changes during therapies for better prognosis.

MUC1 is a large o-glycosylated transmembrane protein that is expressed on the apical surface of healthy breast ductal epithelial cells and on other epithelial surfaces such as the gastrointestinal tract, respiratory tract female reproductive tract, and pancreas [4, 5]. Under normal conditions, MUC1 protects the apical cell surface against microbial infection and dehydration [5]. Both premalignant and malignant epithelial cells and nonmalignant but inflamed epithelial cells over-express abnormal MUC1 [6, 7]. Compared to the normal molecule, abnormal MUC1 is underglycosylated, and the sugars are truncated resulting in exposure of new protein antigenic epitopes. The short sugar epitopes may also stimulate an immune response [8, 9] against antigenically recognizable peptide and glycopeptides epitopes [10]. A potential diagnostic and prognostic value of anti-MUC1 antibodies in sera [11, 12] was studied in the literature but this was not investigated in nipple aspirate fluid (NAF) previously. In contrast to a breast biopsy, aspiration of NAF is a noninvasive method to obtain intraductal material [13]. NAF is composed predominantly of proteinaceous secretions from ductal cells. Therefore, NAF may be representative of the dynamic secretory process of the breast and may include potential markers...
of carcinogenesis [13–15]. Examples of tumor antigens and oncoproteins that have previously been examined in NAF include prostatic-specific antigen, carcinomaembryonic antigen, and c-erb B2 [15–18].

We hypothesized that antibodies against abnormal MUC1 on BC would be present in NAF in higher concentrations in women with BC compared to those with nonmalignant lesions and additionally might be used to predict aggressiveness of BC.

The aim of this feasibility study was to compare anti-MUC1 antibody levels as a diagnostic marker in NAF and in serum of patients with BC and premalignant lesions and in normal breasts. The second objective of this study was to investigate relationship between anti-MUC1 antibody levels in NAF as a predictive marker for tumor aggressiveness.

2. Patients and Methods

2.1. Study Design. Women enrolled in this study were patients intending to have surgery for treatment of BC, premalignant breast disease, and benign breast disease who had been referred to Breast Surgery Unit of Magee-Womens Hospital of University of Pittsburgh Medical Center. Demographics, pretreatment serum, and NAF samples were collected prospectively after approval of the Institutional Review Board. Exclusion criteria were as follows: previous history of cancer, prior breast surgery, radiation, chemotherapy, or endocrine therapy, current use of hormone replacement therapy (estrogen or an estrogen/progesterone combination), current pregnancy, and lactation. All subjects underwent bilateral breast physical exam and had a mammogram and/or ultrasound and breast MRI if indicated.

Collection of NAF samples was performed on anesthetized patients in the operating room prior to surgery for newly diagnosed BC, high risk lesions, and normal breast. Normal breast was defined as contralateral healthy breast of the diseased patients in the operating room prior to surgery for breast disease, and benign breast disease who had been shown in Table 1.

2.2. NAF Collection Procedure. Each breast was massaged for at least 3–5 minutes and the nipple was cleaned with EKG gel and an alcohol wipe. The nipple aspirator (First-Cyte; Cytct Health) was put in place and negative pressure was applied to both breasts at the same time. NAF was collected using 10 μL pipettes and transferred quickly to the laboratory. Depending on the volume of NAF collected, it was stored at −70°C either neat or diluted up to 20-fold with 1x phosphate-buffered saline (PBS).

2.3. Detection of Anti-MUC1 Antibody by ELISA. Enzyme-linked immunosorbent assay (ELISA) method was used to detect anti-MUC1 IgG, IgM, and IgA. Antibodies were measured against a synthetic 100-mer MUC1 peptide corresponding to five tandem repeats of the MUC1 polypeptide core tandem repeat region [19, 20] corresponding to the most abnormal, unglycosylated tumor form of MUC1. Briefly, MUC1-coated Immulon wells (Dynax, Chantilly, VA) and peptide-negative plates were incubated overnight and washed three times with PBS before addition of 100 μL of 2.5% bovine serum albumin in PBS. Serially diluted plasma (1:40 to 1:80 in PBS) was added to MUC1-coated plates and incubated at room temperature. Plates were washed 5 times with 100 μL PBS and 0.1% Tween 20 detergent. Alkaline phosphatase-labeled goat anti-human polyvalent IgM, IgG, and IgA (50 μL) (Sigma-Aldrich, St. Louis, MO) diluted 1:1,000 were added before plates were washed again 5 times with PBS-Tween. Alkaline phosphatase substrate pNPP (100 μL) (Sigma-Aldrich) was added. Plates were incubated before the stop solution (0.5 mol/L NaOH) was added. We used the MRX Revelation plate reader (Thermo Labsystems, Chantilly, VA) to read absorbance values at 405 nm, which were subtracted from absorbance values obtained from antigen-negative plates to account for nonspecific binding. The color change read as an OD value and that value was directly proportional to the amount of antibody present in NAF and serum. The quantity of anti-MUC1 antibodies (IgG, IgM, and IgA) in the serum was represented as absorbance at OD 405 nm.

2.4. Statistical Analyses. All data are presented as mean ± standard deviation. Associations between tumor characteristics and immune-biomarkers level in NAF or serum were examined using the ANOVA test. The difference in levels of NAF and serum MUC1 antibodies between BC, high risk lesions, and normal breast tissue was examined by analysis of ANOVA followed by Tukey’s comparison procedure. OS and DFS were measured using Kaplan-Meier method. A P value less than 0.05 was considered statistically significant. All statistical tests were performed using SPSS, version 21.0, software (SPSS Inc., Chicago, IL).

3. Results

One hundred and twenty NAF samples were collected prospectively from 77 women who underwent breast surgery. Among them there were 52 BC patients but NAF was obtained in 44 breasts with cancer. The rest of 76 NAF samples were collected from the following: 7 (6%) had in situ lesions, 18 (15%) had atypia (15 ductal type, 3 lobular type), and 51 (43%) had normal breast tissue.

The majority of women (93.6%) were older than 40 years. The mean age of women with BC was 54 ± 10 years (range 40–84). The mean follow-up period was 73 ± 18 months with range of 51 to 187 months. There were 4 recurrences, 2 of which were local recurrence and 2 of which were distant metastases. The 6-year OS and DFS were 98.1% and 92.3%, respectively. Tumor characteristics of patients with malignant disease are shown in Table 1.
There was no significant difference in levels of anti-MUC1 antibodies between BC, in situ lesions, atypical hyperplasia, and normal breast tissue either in NAF or in serum (Figures 1 and 2). However, in the NAF of women diagnosed with BC, anti-MUC1 IgG was higher in triple negative patients \((P = 0.02)\). NAF anti-MUC1 IgA levels in cancers with LVI and in Her2-neu positive cancers were significantly higher than those without these features \((P = 0.005, P = 0.02, \text{resp.})\). High levels of serum anti-MUC1 IgG were significantly associated with ER negative disease and with disease recurrence (both at \(P = 0.01\)). Serum anti-MUC1 IgM levels were higher in patients who had tumor that was equal or smaller than 2 cm \((P = 0.03)\). Statistically significant relationships between NAF or serum levels of anti-MUC1 antibodies as immune biomarkers and tumor characteristics are shown in Table 2. There was no relationship between lymph node positivity, grade, and Ki 67 status and anti-MUC1 antibody levels.

### 4. Discussion

The relationship between MUC1 and tumor characteristics in BC was evaluated in several IHC studies but results of these studies are conflicting. Some studies show that overexpression of MUC1 is associated with better tumor behavior [21,22], absence of regional recurrence, and distant metastasis, but others demonstrate the opposite [23, 24]. On the other hand, the presence and significance of anti-MUC1 antibodies have not been previously evaluated in NAF.

Measurement of anti-MUC1 antibody levels is more practical and advantageous than determination of MUC1 antigens, because regardless of tumor size, a tiny bit of antigen made by a few premalignant or malignant cells can drain to the nearest lymph node and induce an immune response that can be detected in NAF. Furthermore, according to an

---

**Table 1: Pathological characteristics of breast cancer patients.**

| Tumor characteristics | Patient number | % |
|-----------------------|---------------|---|
| All patients          | 52            | 100|
| Tumor size (T)        |               |    |
| T ≤ 2 cm              | 38            | 73 |
| T > 2 cm              | 14            | 27 |
| Lymph node (N)        |               |    |
| N = 0                 | 39            | 75 |
| N = 1, 2              | 13            | 25 |
| Estrogen receptor     |               |    |
| (−)                   | 10            | 19 |
| (+)                   | 42            | 81 |
| Progesterone receptor |               |    |
| (−)                   | 13            | 25 |
| (+)                   | 39            | 75 |
| Her2-neu              |               |    |
| (−)                   | 41            | 79 |
| (+)                   | 8             | 15 |
| Missing               | 3             | 6  |
| Triple negative       |               |    |
| Absent                | 43            | 83 |
| Present               | 6             | 11 |
| Missing               | 3             | 6  |
| Tumor grade           |               |    |
| Grade 1               | 10            | 19 |
| Grade 2               | 27            | 52 |
| Grade 3               | 15            | 29 |
| LVI                   |               |    |
| Absent                | 42            | 81 |
| Present               | 7             | 13 |
| Missing               | 3             | 6  |
| ECE                   |               |    |
| Absent                | 48            | 92 |
| Present               | 4             | 8  |
| Ki-67 receptor        |               |    |
| <15                   | 10            | 19 |
| ≥15                   | 13            | 25 |
| Missing               | 29            | 56 |

LVI: lymphovascular invasion and ECE: extracapsular extension.
interesting study presented by Larrain et al., after serums of breast cancer patients that were combined with incubated breast tissues had different pathologic diagnosis such as normal, benign, and malignant, they found the reduction in anti-MUC1 antibody and antigen reactivity to be more in breast cancer tissues than benign breast tissues [25]. On the other hand, NAF is an inexpensive and feasible method that may reflect the tumor microenvironment. In addition, NAF which is noninvasive method can be easily collected in outpatient department from women, despite the fact that it was collected under general anesthesia from patients who had pathologic diagnosis of breast tumor in our study [15, 18]. Moreover, antibody measurement in NAF enables more correct determination than in serum of anti-MUC1 IgA, because IgA is epithelial surface antibody. In this study, we demonstrated that anti-MUC1 IgG, IgM, and IgA antibodies could be detected in NAF using ELISA and that high level of anti-MUC1 IgG antibody in NAF was significantly associated with triple negative tumor phenotype (ER−, PR−, and Her 2−) and anti-MUC1 IgA antibodies were also significantly higher in the NAF of patients with LVI and Her2-neu-positive disease. These results suggest that high levels of anti-MUC1 antibody in NAF were associated with poor tumor characteristics. However, several immunohistochemical (IHC) studies have also demonstrated that MUC1 expression is associated with ER and PR positivity [21, 22, 24]. According to Rakha et al. high expression of MUC1 was associated with ER positivity, smaller size, and low-grade tumors [22]. They also found a negative association between expression of MUC1 and presence of lymph node metastasis, regional recurrence, and distant metastasis [22]. Garbar et al. showed that higher IHC staining of MUC1 was observed in PR positive tumors [24]. On the other hand, they also showed that MUC1 expression was higher in lymph node metastases when compared to primary tumor tissue [24]. McGuckin et al. showed that high level of MUC1 expression was associated with both axillary node metastasis and ER positivity [23]. Also, in our study, high serum levels of anti-MUC1 antibodies are associated with both ER negative and smaller size tumors. Favorable prognostic effects of MUC1 are seen in association with ER positivity, while poor prognostic may be associated with the inhibition of integrin and E-cadherin mediated cell adhesion and the binding of MUC1 to ICAM-1, which is thought to play a role in cell migration [7, 11, 21]. In addition, high level of anti-MUC1 antibody suggests the immunogenic potential of MUC1 [26]. The literature suggests that MUC1 affords protection against disease progression as a consequence of natural humoral immunity [26], consistent with a significant association of lymph node negativity and improved OS in patients with high level of serum anti-MUC1 IgG and IgM antibody [21, 27]. Studies by von Mensdorff-Pouilly et al. describe an inverse correlation between serum anti-MUC1 antibody and disease extent [27]. Herein, we demonstrated an association between anti-MUC1 IgG in the serum and recurrent disease; in spite of the fact that there was no relationship of lymph node positivity, tumor grade and Ki67 status between anti-MUC1 antibodies levels, there was a statistically significant association between anti-MUC1

Table 2: Anti-MUC1 antibody levels of breast cancer patients in NAF and serum samples.

| Tumor characteristic* | Anti-MUC1 levels (mean ± SD) (OD 405 nm) | P   | IgG | P   | IgM | P   | IgA | P   |
|-----------------------|-------------------------------------------|-----|-----|-----|-----|-----|-----|-----|
|                       | NAF (n = 44)                              |     |     |     |     |     |     |
| Triple negative       |                                            |     |     |     |     |     |     |
| Absent (n = 37)       | 0.10 ± 0.07                               | 0.12| 0.17± 0.16 | 0.23 ± 0.16 | 0.90 |
| Present (n = 6)       | 0.20 ± 0.20                               | 0.29± 0.23 | 0.24 ± 0.09 | 0.02 |
| Her2-neu              |                                            |     |     |     |     |     |     |
| (−) (n = 37)          | 0.11 ± 0.11                               | 0.17± 0.16 | 0.21 ± 0.12 | 0.005|
| (+) (n = 6)           | 0.14 ± 0.08                               | 0.25± 0.25 | 0.36 ± 0.25 |     |
| LVI                   |                                            |     |     |     |     |     |     |
| (−) (n = 36)          | 0.11 ± 0.11                               | 0.19± 0.19 | 0.21 ± 0.12 | 0.02 |
| (+) (n = 6)           | 0.10 ± 0.27                               | 0.16± 0.10 | 0.40 ± 0.25 |     |
|                       | Serum (n = 51)                            |     |     |     |     |     |     |
| Estrogen receptor     |                                            |     |     |     |     |     |     |
| (−) (n = 9)           | 0.53 ± 0.83                               | 0.99± 0.48 | 0.26 ± 0.09 | 0.70 |
| (+) (n = 42)          | 0.16 ± 0.19                               | 0.97± 0.60 | 0.29 ± 0.19 |     |
| Tumor size (T)        |                                            |     |     |     |     |     |     |
| T ≤ 2 cm (n = 38)     | 0.26 ± 0.46                               | 1.08± 0.63 | 0.27 ± 0.15 | 0.03 |
| T > 2 cm (n = 13)     | 0.12 ± 0.08                               | 0.68± 0.28 | 0.32 ± 0.25 |     |
| Recurrence            |                                            |     |     |     |     |     |     |
| Absent (n = 47)       | 0.18 ± 0.21                               | 0.98± 0.59 | 0.29 ± 0.18 | 0.24 |
| Present (n = 4)       | 0.70 ± 1.30                               | 0.93± 0.59 | 0.18 ± 0.10 |     |

*One missing data in NAF sample for triple negativity and Her2-neu status and two missing data in NAF samples for LVI status from 44 malignant breast lesions. One missing data for serum samples from 52 patients with malignant. LVI: lymphovascular invasion and NAF: nipple aspirate fluid.
IgA in NAF with LVI. Some of these results in the literature seem contradictory in our results. However, these studies have limited the number of samples similar to our study. Therefore, current knowledge about the response of anti-MUC1 antibody of patients with different patterns of tumor receptors is not sufficient, but it was shown that MUC1 expression is related to ER status [23]. It is possible that anti-MUC1 antibody in ER negative tumor does not afford the same protective effect in patients with ER positive BC [28]. The conflicting results belong to recurrence and other tumor characteristics for each of MUC1 and anti-MUC1 antibody may depend on this theory.

In this study, we investigated whether anti-MUC1 antibody, in either NAF or serum, could discriminate between BC, premalignant breast lesion, and normal breast, but we did not demonstrate a significant difference. Ghosh et al. showed using IHC that overexpression of underglycosylated MUC1 localized markedly in normal breast tissue adjacent to tumors [29]. On the other hand, Tang et al. demonstrated that anti-MUC1 IgG immune complex in the serum of patients with BC and benign breast lesion was higher than in healthy women [30]. In our study, there were very few patients that had only benign breast lesions and few healthy women. This limits our demonstration of such findings in serum, because high serum level of anti-MUC1 antibodies can be found in patients with benign breast lesions, after breast inflammation and benign proliferative condition such as pregnancy [6, 31]. In our study discrimination features of anti-MUC1 antibodies were investigated for benign lesions in NAF as well, but it had no significant difference between benign breast lesions and healthy women. A small number of patients with bilateral normal breasts (n = 4) and additionally NAF were obtained from contralateral side of premalignant or malignant breasts which might not be considered as benign lesions and normal breasts. Although it is possible that NAF obtained from each breast in the same patient reflects the microenvironment itself, Kuerer et al. reported that Her2-neu in NAF was seen in bilateral breasts from women who had unilateral invasive cancer. They found that levels of Her2-neu were significantly higher in the affected breast than in the unaffected breast [16].

Although our study had a follow-up period of an average of 73 months, we were unable to investigate the relationship between prognosis in BC and immune biomarkers, due to the small sample size of the study. This is the first feasibility study which investigated anti-MUC1 antibody in NAF and its relationship with tumor characteristics. Our results warrant a larger study on anti-MUC1 antibodies in NAF to validate the relationship between tumor aggressiveness and immune biomarkers.

5. Conclusion

This result shows that NAF containing anti-MUC1 antibody could be a reliable biomarker to predict tumor aggressiveness in BC. A larger study will be needed to confirm these data and to investigate the potential of anti-MUC1 antibodies in NAF and serum to predict disease outcome.

Disclosure

This study was presented at the 8th International Symposium on the Breast, Santa Monica, 2015.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgment

This study was awarded pilot grant from Dr. Susan Love Research foundation.

References

[1] Globocan, “Estimated cancer incidence, mortality and prevalence worldwide in 2012,” 2012, http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
[2] National Cancer Institute, “SEER Stat Fact Sheets: Breast cancer,” http://seer.cancer.gov/statfacts/html/breast.html.
[3] R. de Gelder, E. A. M. Heijnslijk, J. Frachefoud, G. Draisma, and H. J. de Koning, “The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy,” International Journal of Cancer, vol. 137, no. 1, pp. 165–172, 2015.
[4] D. W. Kufe, “MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches,” Oncogene, vol. 32, no. 9, pp. 1073–1081, 2013.
[5] M. Brayman, A. Thathiah, and D. D. Carson, “MUC1: a multifunctional cell surface component of reproductive tissue epithelia,” Reproductive Biology and Endocrinology, vol. 2, article 4, 2004.
[6] P. L. Beatty and O. J. Finn, “Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas,” Annals of the New York Academy of Sciences, vol. 1284, no. 1, pp. 52–56, 2013.
[7] S. Von Mensdorff-Pouilly, M. Moreno, and R. H. M. Verheijen, “Natural and induced humoral responses to MUC1,” Cancers, vol. 3, no. 3, pp. 3073–3103, 2011.
[8] S. E. Baldus and F.-G. Hanisch, “Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia,” Advances in Cancer Research, vol. 79, pp. 201–248, 2000.
[9] J. J. Rahn, L. Dabbagh, M. Pasdar, and J. C. Hugh, “The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature,” Cancer, vol. 91, no. 11, pp. 1973–1982, 2001.
[10] S. J. Genteler, “MUC1, the renaissance molecule,” Journal of Mammary Gland Biology and Neoplasia, vol. 6, no. 3, pp. 339–353, 2001.
[11] E. Yang, X. F. Hu, and P. X. Xing, “Advances of MUC1 as a target for breast cancer immunotherapy,” Histology and Histopathology, vol. 22, no. 8, pp. 905–922, 2007.
[12] S. von Mensdorff-Pouilly, A. A. Verstraeten, P. Kenemans et al., “Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin,” Journal of Clinical Oncology, vol. 18, no. 3, pp. 574–583, 2000.
Disease Markers

[13] P. Klein, E. Glaser, L. Grogan et al., "Biomarker assays in nipple aspirate fluid," *Breast Journal*, vol. 7, no. 6, pp. 378–387, 2001.

[14] P. M. Klein and J. A. Lawrence, "Lavage and nipple aspiration of breast ductal fluids: a source of biomarkers for environmental mutagenesis," *Environmental and Molecular Mutagenesis*, vol. 39, no. 2–3, pp. 127–133, 2002.

[15] F. Mannello, V. Medda, and G. A. Tonti, "Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients," *Expert Review of Proteomics*, vol. 6, no. 1, pp. 43–60, 2009.

[16] H. M. Kuerer, P. A. Thompson, S. Krishnamurthy et al., "High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer," *Clinical Cancer Research*, vol. 9, no. 2, pp. 601–605, 2003.

[17] J. E. Lang and H. M. Kuerer, "Breast ductal secretions: clinical features, potential uses, and possible applications," *Cancer Control*, vol. 14, no. 4, pp. 350–359, 2007.

[18] F. Mannello, "Analysis of the intraductal microenvironment for the early diagnosis of breast cancer: identification of biomarkers in nipple-aspirate fluids," *Expert Opinion on Medical Diagnostics*, vol. 2, no. 11, pp. 1221–1231, 2008.

[19] D. W. Cramer, L. Titus-Ernstoff, J. R. McKolanis et al., "Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer," *Cancer Epidemiology, Biomarkers & Prevention*, vol. 14, no. 5, pp. 1125–1131, 2005.

[20] Y. Kotera, J. D. Fontenot, G. Pecher, R. S. Metzgar, and O. J. Finn, "Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients," *Cancer Research*, vol. 54, no. 11, pp. 2856–2860, 1994.

[21] B. V. Sinn, G. von Minckwitz, C. Denkert et al., "Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer," *Annals of Oncology*, vol. 24, no. 9, pp. 2316–2324, 2013.

[22] E. A. Rakha, R. W. G. Boyce, D. A. El-Rehim et al., "Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer," *Modern Pathology*, vol. 18, no. 10, pp. 1295–1304, 2005.

[23] M. A. McGuckin, M. D. Walsh, B. G. Hohn, B. G. Ward, and R. G. Wright, "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," *Human Pathology*, vol. 26, no. 4, pp. 432–439, 1995.

[24] C. Garbar, C. Mascaux, H. Curé, and A. Bensussan, "MUC1/CD227 immunohistochemistry in routine practice is a useful biomarker in breast cancers," *Journal of Immunoassay and Immunochemistry*, vol. 34, no. 3, pp. 232–245, 2013.

[25] M. T. I. Larrain, A. G. Colussi, S. O. Demichelis et al., "Humoral immune response against tumoral mucin 1 (MUC1) in breast cancer patients," *The International Journal of Biological Markers*, vol. 28, no. 3, pp. 318–325, 2013.

[26] B. Piura and E. Piura, "Autoantibodies to tumor-associated antigens in breast carcinoma," *Journal of Oncology*, vol. 2010, Article ID 264926, 14 pages, 2010.

[27] S. von Mensdorff-Pouilly, M. M. Gourevitch, P. Kenemans et al., "Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours," *European Journal of Cancer A*, vol. 32, no. 8, pp. 1325–1331, 1996.

[28] S. Vassilaros, A. Tsibanis, A. Tsikkinis, G. A. Pietersz, I. F. C. McKenzie, and V. Apostolopoulos, "Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1," *Immunotherapy*, vol. 5, no. 11, pp. 1177–1182, 2013.

[29] S. K. Ghosh, P. Pantazopoulos, Z. Medarova, and A. Moore, "Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues," *Clinical Breast Cancer*, vol. 13, no. 2, pp. 109–118, 2013.

[30] Y. Tang, L. Wang, P. Zhang et al., "Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in *Escherichia coli*," *Clinical and Vaccine Immunology*, vol. 17, no. 12, pp. 1903–1908, 2010.

[31] M. V. Croce, M. T. Isla-Larrain, M. R. Price, and A. Segal-Eiras, "Detection of circulating mammary mucin (MUC1) and MUC1 immune complexes (MUC1-CIC) in healthy women," *The International Journal of Biological Markers*, vol. 16, no. 2, pp. 112–120, 2001.